FGFR Inhibition in Advanced UC

By Vadim Koshkin, MD, Amanda Nizam, MD - Last Updated: September 23, 2024

Vadim Koshkin, MD, from the University of California, San Francisco, reviews the phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma from ESMO 2024.

He highlights the motivation behind testing a different FGFR inhibitor, the rationale behind including an unselected wild-type cohort, and the future of further developing this regimen.

The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025

Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.

BRAVO Study: Blue Light Cystoscopy Reduces Recurrence in Patients With NMIBC

Emily MenendezUrothelial Carcinoma Diagnostics | March 20, 2025

Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.

Co-PSMA Trial: Head-to-Head Comparison of 64Cu-SAR-bis-PSMA vs 68Ga-PSMA-11

Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025

Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...

Impact of Insurance Status on Survival Outcomes in Metastatic RCC

Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025

Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.

Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT

Phouc T. Tran, MD, PhDProstate Cancer | March 18, 2025

Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.

FGFR Inhibition in Advanced UC

Related Posts